Nevertheless, it has been proposed that fusion proteins, such as BCR-ABL, commonly found in chronic myelogenous leukemia, following t(9:22) translocation, or PML-RARα, following t(15:17) translocation (which typically occurs in acute promyelocytic leukemia), can contribute to a malignant phenotype due to their permanently active domains, but also by disturbing the ceRNA balances on the RNA level [51,52]. This evidence concerns the gene PML and acute promyelocytic leukemia.